Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel Free CNSL Stock Alerts

Cambridge Nutritional Sciences (CNSL) Competitors

GBX 1.70 +0.15 (+9.68%)
As of 12:31 PM Eastern
Compare

CNSL vs. AVO, ODX, MHC, SUN, and BELL

Should you buy Cambridge Nutritional Sciences stock or one of its competitors? Cambridge Nutritional Sciences's main competitors and comparable companies include Advanced Oncotherapy (AVO), Omega Diagnostics Group (ODX), MyHealthChecked (MHC), Surgical Innovations Group (SUN), and Belluscura (BELL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Cambridge Nutritional Sciences compare to Advanced Oncotherapy?

Advanced Oncotherapy (LON:AVO) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

In the previous week, Advanced Oncotherapy's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
Advanced Oncotherapy Neutral
Cambridge Nutritional Sciences Neutral

Advanced Oncotherapy has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.911, meaning that its share price is 91% more volatile than the broader market.

17.8% of Advanced Oncotherapy shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 47.5% of Advanced Oncotherapy shares are owned by company insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Advanced Oncotherapy has a net margin of 0.00% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Advanced Oncotherapy's return on equity of -67.34% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
Cambridge Nutritional Sciences -83.53%-69.62%-2.36%

Cambridge Nutritional Sciences has higher revenue and earnings than Advanced Oncotherapy. Advanced Oncotherapy is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83

Summary

Cambridge Nutritional Sciences beats Advanced Oncotherapy on 6 of the 10 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Omega Diagnostics Group?

Cambridge Nutritional Sciences (LON:CNSL) and Omega Diagnostics Group (LON:ODX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Cambridge Nutritional Sciences has a beta of 1.911, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, indicating that its stock price is 285% more volatile than the broader market.

Omega Diagnostics Group has a net margin of -51.15% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Omega Diagnostics Group's return on equity of -29.14% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Cambridge Nutritional Sciences has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Omega Diagnostics Group Neutral

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cambridge Nutritional Sciences and Omega Diagnostics Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to MyHealthChecked?

Cambridge Nutritional Sciences (LON:CNSL) and MyHealthChecked (LON:MHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled MyHealthChecked'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
MyHealthChecked Neutral

MyHealthChecked has lower revenue, but higher earnings than Cambridge Nutritional Sciences. MyHealthChecked is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. Comparatively, 0.7% of MyHealthChecked shares are held by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Comparatively, 9.3% of MyHealthChecked shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MyHealthChecked has a net margin of -49.51% compared to Cambridge Nutritional Sciences' net margin of -83.53%. MyHealthChecked's return on equity of -22.78% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
MyHealthChecked -49.51%-22.78%-8.18%

Cambridge Nutritional Sciences has a beta of 1.911, suggesting that its share price is 91% more volatile than the broader market. Comparatively, MyHealthChecked has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Summary

Cambridge Nutritional Sciences beats MyHealthChecked on 6 of the 11 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Surgical Innovations Group?

Surgical Innovations Group (LON:SUN) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Surgical Innovations Group has higher revenue and earnings than Cambridge Nutritional Sciences. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.29N/A-£0.10N/A
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83

In the previous week, Surgical Innovations Group had 7 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 7 mentions for Surgical Innovations Group and 0 mentions for Cambridge Nutritional Sciences. Cambridge Nutritional Sciences' average media sentiment score of 0.00 beat Surgical Innovations Group's score of -0.03 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Surgical Innovations Group Neutral
Cambridge Nutritional Sciences Neutral

Surgical Innovations Group has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.911, meaning that its stock price is 91% more volatile than the broader market.

2.8% of Surgical Innovations Group shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 22.2% of Surgical Innovations Group shares are owned by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Surgical Innovations Group has a net margin of -4.96% compared to Cambridge Nutritional Sciences' net margin of -83.53%. Surgical Innovations Group's return on equity of -6.04% beat Cambridge Nutritional Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
Cambridge Nutritional Sciences -83.53%-69.62%-2.36%

Summary

Surgical Innovations Group and Cambridge Nutritional Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Cambridge Nutritional Sciences compare to Belluscura?

Cambridge Nutritional Sciences (LON:CNSL) and Belluscura (LON:BELL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Cambridge Nutritional Sciences has a net margin of -83.53% compared to Belluscura's net margin of -2,243.45%. Cambridge Nutritional Sciences' return on equity of -69.62% beat Belluscura's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences-83.53% -69.62% -2.36%
Belluscura -2,243.45%-97.35%-43.53%

1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. Comparatively, 0.2% of Belluscura shares are held by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are held by company insiders. Comparatively, 7.1% of Belluscura shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cambridge Nutritional Sciences has a beta of 1.911, meaning that its share price is 91% more volatile than the broader market. Comparatively, Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Cambridge Nutritional Sciences has higher revenue and earnings than Belluscura. Belluscura is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.83
Belluscura£1.80M1.67-£29.55M-£13.10N/A

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled Belluscura'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
Belluscura Neutral

Summary

Cambridge Nutritional Sciences beats Belluscura on 10 of the 11 factors compared between the two stocks.

Get Cambridge Nutritional Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSL vs. The Competition

Export
MetricCambridge Nutritional SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£4.05M£5.37B£7.11B£2.80B
Dividend YieldN/A1.80%2.53%6.18%
P/E Ratio2.8324.63274.42366.17
Price / Sales0.5041.67600.7289,425.29
Price / CashN/A32.6877.3827.89
Price / Book0.435.6910.926.83
Net Income-£3.03M£152.11M£3.50B£5.89B
7 Day Performance14.79%-2.01%-2.07%-0.75%
1 Month Performance-5.92%-5.42%-6.32%16.84%
1 Year Performance-39.42%2.71%8.92%16.40%

Cambridge Nutritional Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNSL
Cambridge Nutritional Sciences
N/AGBX 1.70
+9.7%		N/A-49.7%£4.05M£8.06M2.833,200
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91
MHC
MyHealthChecked
N/AGBX 9.15
+1.7%		N/A-8.5%£4.76M£3.22MN/A16
SUN
Surgical Innovations Group
N/AGBX 0.40
-5.9%		N/A-24.9%£3.96M£11.60MN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CNSL) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...
Paradigm Press | Sponsoredtc pixel
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...
Stansberry Research | Sponsoredtc pixel
The SEC Just Opened The Floodgates…
The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...
StocksToTrade | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel